3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1
1
Status
Recruiting
6
Not yet recruiting
3
Active not recruiting
3
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Conditions
Multiple Myeloma
2
Immunoglobulin Light-chain Amyloidosis
1
Amyloidosis
1
Interventions
Carboplatin
79
Cisplatin
74
Bevacizumab
62
Radiotherapy
59
Drug Therapy
57
Capecitabine
57
Oxaliplatin
56
tislelizumab
54
toripalimab
45
Paclitaxel
44
Gemcitabine
43
pembrolizumab
40
anlotinib
40
Specimen Handling
39
sintilimab
37
Cyclophosphamide
34
130-nm albumin-bound paclitaxel
34
Injections
30
Pemetrexed
28
camrelizumab
26
Surgical Procedures, Operative
26
Magnetic Resonance Spectroscopy
25
lenvatinib
24
apatinib
23
Docetaxel
23
Etoposide
22
S 1 (combination)
21
Fluorouracil
21
Immune Checkpoint Inhibitors
20
Biopsy
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Not yet recruiting
×
belantamab mafodotin
×
Clear all
NCT07614360
2026-05-29
DREAMM-16
GlaxoSmithKline
Phase 2
Not yet recruiting
120 enrolled
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled
NCT05874193
2026-02-05
COSTA
Duke University
Phase 2
Not yet recruiting
33 enrolled